Affinia Therapeutics Inc. (AFTX)

Affinia Therapeutics was planning to go public, but the IPO was withdrawn on Dec 2, 2022.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 8.06M
Net Income (ttm) -39.77M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About AFTX

Affinia Therapeutics is a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in patients with both rare and prevalent devastating diseases. We created our proprietary Affinia Rationally-designed Therapies (ART) platform to develop these novel therapies, focusing on the three key components of a gene therapy: capsids, which are the outer shells of a virus used to deliver the genetic code to tissues to treat a disease; promoters, which control how the cells read the genetic cod... [Read more]

Industry Health Care
Sector Biotechnology
Founded 2019
Employees 63
Stock Exchange NASDAQ
Ticker Symbol AFTX
Full Company Profile

Financial Performance

Financial Statements


Gene therapy biotech Affinia Therapeutics files for a $100 million IPO

Affinia Therapeutics, a preclinical biotech developing novel gene therapies for rare diseases and cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

2 years ago - Renaissance Capital

Affinia Therapeutics IPO Registration Document (S-1)

Affinia Therapeutics has filed to go public with an IPO on the NASDAQ.

2 years ago - SEC

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs

Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to...

2 years ago - GLOBE NEWSWIRE